Stemtech Stock Today
| STEK Stock | USD 0 0.0002 14.29% |
PerformanceWeakest
| Odds Of DistressLow
|
Stemtech is selling for 0.0012 as of the 24th of December 2025. This is a 14.29% down since the beginning of the trading day. The stock's last reported lowest price was 0.0011. Stemtech has about a 25 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 24th of November 2025 and ending today, the 24th of December 2025. Click here to learn more.
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. The company has 48.63 M outstanding shares. More on Stemtech
Moving against Stemtech OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Stemtech OTC Stock Highlights
| Thematic Idea | IT (View all Themes) |
| Business Concentration | IT, Drug Manufacturers—Specialty & Generic, Healthcare, Computing (View all Sectors) |
Stemtech [STEK] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Stemtech's market, we take the total number of its shares issued and multiply it by Stemtech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Stemtech conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 48.63 M outstanding shares.
Stemtech currently holds about 399.73 K in cash with (1.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Stemtech Probability Of Bankruptcy
Ownership AllocationStemtech shows a total of 48.63 Million outstanding shares. Stemtech has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 63.6 % of Stemtech outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Stemtech Ownership Details
Stemtech Risk Profiles
| Mean Deviation | 10.81 | |||
| Standard Deviation | 14.53 | |||
| Variance | 211.09 | |||
| Risk Adjusted Performance | (0.09) |
Stemtech Stock Against Markets
Picking the right benchmark for Stemtech otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Stemtech otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Stemtech is critical whether you are bullish or bearish towards Stemtech at a given time. Please also check how Stemtech's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Stemtech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Stemtech Corporate Management
Elected by the shareholders, the Stemtech's board of directors comprises two types of representatives: Stemtech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stemtech. The board's role is to monitor Stemtech's management team and ensure that shareholders' interests are well served. Stemtech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stemtech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Arnold | CEO Director | Profile | |
| James Cardwell | Chief Officer | Profile | |
| Alejandro Carrillo | Managing Markets | Profile | |
| John Meyer | COO Pres | Profile |
Other Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.